U.S. Markets open in 2 hrs 2 mins

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact The Firm


The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Stemline Therapeutics, Inc. (STML) (Stemline or the “Company”) common stock issued in connection with the Company’s secondary public offering on or about January 20, 2017, or on the open market between January 6, 2017 and February 1, 2017, inclusive (the “Class Period). Investors who wish to become proactively involved in the litigation have until April 4, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Stemline during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 and the Securities Act of 1933 by virtue of the defendants’ failure to disclose in connection with Stemline’s secondary public offering and during the Class Period that a cancer patient in a Stemline clinical trial died from a severe side effect tied to SL-401 on January 18, 2017.

According to the complaint, following a February 2, 2017 article and press release regarding the death, the value of Stemline shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Stemline during the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005010/en/